Figure 1.
Figure 1. Characteristics of generated CMVST lines and degree of matching with screened subjects. (A) T-cell expansion of CMVSTs achieved over a 20-day period based on cell counting using trypan blue exclusion (n = 8). Phenotype of the expanded CMVST lines on the day of cryopreservation (mean ± standard error of the mean [SEM], n = 8) (B) and frequency of antigen-specific T cells as determined by IFN-γ ELISPOT assay (C) after overnight stimulation of CMVSTs with IE1 and pp65 antigen-spanning PepMixes. Results are reported as SFCs per 2 × 105 VSTs plated. CMVST lines with a total of ≥30 SFCS per 2 × 105 were considered to be positive (n = 8). (D) Number of matching HLA antigens (of 8 total) of CMVST lines identified for clinical use with recipient HLA of screened patients (n = 29).

Characteristics of generated CMVST lines and degree of matching with screened subjects. (A) T-cell expansion of CMVSTs achieved over a 20-day period based on cell counting using trypan blue exclusion (n = 8). Phenotype of the expanded CMVST lines on the day of cryopreservation (mean ± standard error of the mean [SEM], n = 8) (B) and frequency of antigen-specific T cells as determined by IFN-γ ELISPOT assay (C) after overnight stimulation of CMVSTs with IE1 and pp65 antigen-spanning PepMixes. Results are reported as SFCs per 2 × 105 VSTs plated. CMVST lines with a total of ≥30 SFCS per 2 × 105 were considered to be positive (n = 8). (D) Number of matching HLA antigens (of 8 total) of CMVST lines identified for clinical use with recipient HLA of screened patients (n = 29).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal